Gastrointestinal Stromal Tumor is rare, making up less than 1% of all gastrointestinal tumors. Each year, about 4,000 to 6,000 adults in the United States will be diagnosed with a GIST. About 60% of GISTs begin in the stomach and around 35% increase in the small intestine. The outstanding types of Gastrointestinal Stromal Tumor usually start in the rectum, colon, and throat. Most people diagnosed with a GIST are in their 60s. They seldom occur in somebody more youthful than 40.
The 5-year survival rate tells you what percent of people live at least five years after the cancer is found. The percent indicates how many out of 100. The 5-year survival rate for people with a Gastrointestinal Stromal Tumor depends on various factors, including unique biologic characteristics of the tumor, the type of treatment, and the risk that it will come back after treatment.
The American Cancer Society’s most recent data possible is from 2003 to 2009. This means that these endurance rates do not show the results of better diagnosis or treatment potential since then. Based on that data, the overall 5-year survival rate of people diagnosed with a malignant
Gastrointestinal Stromal Tumor is 76%. If the tumor has not spread from the organ where it started, the 5-year survival rate is 91%. If cancer has spread to encompassing tissues or organs, the 5-year survival rate is 74%. If cancer had spread to a distant part of the body when it was first diagnosed, the durability rate is 48%.